These findings align with growing evidence indicating that SGLT2 inhibitors may have liver-protective effects, potentially by reducing hepatic steatosis, inflammation, or fibrosis in patients with T2DM and NAFLD [15]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.